Literature DB >> 12070531

Potential use of beta(3)-adrenoceptor antagonists in heart failure therapy.

Stéphane Moniotte1, Jean-Luc Balligand.   

Abstract

Recently, a functional, negatively inotropic, beta(3)-adrenoceptor was characterized in the human heart. Several studies now suggest that this receptor might play an important role in the pathophysiology of heart failure, by counterbalancing the effects of a beta(1)- and beta(2)-stimulation. Therefore, this review summarizes the rationale and effects of beta-adrenergic blockade in chronic heart failure and specifically addresses the question of the potential use of beta(3)-adrenoceptor antagonists in the treatment of heart failure and other pathophysiological conditions associated with a decreased cardiac contractility.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12070531     DOI： 10.1111/j.1527-3466.2002.tb00079.x

Source DB:  PubMed          Journal:  Cardiovasc Drug Rev        ISSN： 0897-5957


  13 in total

Review 1.  [On the function of beta3-adrenoceptors in the human heart: signal transduction, inotropic effect and therapeutic prospects].

Authors:  Christian Pott; Dirk Steinritz; Andreas Napp; Wilhelm Bloch; Robert H G Schwinger; Klara Brixius
Journal:  Wien Med Wochenschr       Date:  2006-08

2.  Up-regulation and functional effect of cardiac β3-adrenoreceptors in alcoholic monkeys.

Authors:  Heng-Jie Cheng; Kathleen A Grant; Qing-Hua Han; James B Daunais; David P Friedman; Satoshi Masutani; William C Little; Che-Ping Cheng
Journal:  Alcohol Clin Exp Res       Date:  2010-05-12       Impact factor: 3.455

Review 3.  Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system.

Authors:  An L Moens; Ronghua Yang; Vabren L Watts; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2010-02-23       Impact factor: 5.000

4.  Mitochondriocentric pathway to cardiomyocyte necrosis in aldosteronism: cardioprotective responses to carvedilol and nebivolol.

Authors:  Yaser Cheema; Jonathan N Sherrod; Wenyuan Zhao; Tieqiang Zhao; Robert A Ahokas; Yao Sun; Ivan C Gerling; Syamal K Bhattacharya; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2011-07       Impact factor: 3.105

5.  Role of β-blocker therapy in pediatric heart failure.

Authors:  Akash R Patel; Robert E Shaddy
Journal:  Ped Health       Date:  2010

6.  Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism.

Authors:  Jochen Steppan; Sungwoo Ryoo; Karl H Schuleri; Chris Gregg; Rani K Hasan; A Ron White; Lukasz J Bugaj; Mehnaz Khan; Lakshmi Santhanam; Daniel Nyhan; Artin A Shoukas; Joshua M Hare; Dan E Berkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

7.  Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor.

Authors:  An L Moens; Jordan S Leyton-Mange; Xiaolin Niu; Ronghua Yang; Oscar Cingolani; Elisabeth K Arkenbout; Hunter C Champion; Djahida Bedja; Kathleen L Gabrielson; Juan Chen; Yong Xia; Ashley B Hale; Keith M Channon; Marc K Halushka; Norman Barker; Floris L Wuyts; Pawel M Kaminski; Michael S Wolin; David A Kass; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2009-09-18       Impact factor: 5.000

8.  β3-Adrenergic receptor antagonist improves exercise performance in pacing-induced heart failure.

Authors:  Satoshi Masutani; Heng-Jie Cheng; Atsushi Morimoto; Hiroshi Hasegawa; Qing-Hua Han; William C Little; Che Ping Cheng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-07-19       Impact factor: 4.733

9.  The changes in beta-adrenoceptor-mediated cardiac function in experimental hypothyroidism: the possible contribution of cardiac beta3-adrenoceptors.

Authors:  E Arioglu; S Guner; I Ozakca; V M Altan; A T Ozcelikay
Journal:  Mol Cell Biochem       Date:  2009-09-01       Impact factor: 3.396

Review 10.  The influence of diabetes on cardiac beta-adrenoceptor subtypes.

Authors:  V Melih Altan; Ebru Arioglu; Sahika Guner; A Tanju Ozcelikay
Journal:  Heart Fail Rev       Date:  2007-03-16       Impact factor: 4.654
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.